hit counter
Brainstorm Cell Therapeutics Inc. (BCLI) Stock News Sentiment & Price - Sentifly
BCLI - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Brainstorm Cell Therapeutics Inc. (BCLI)

USA
Biotechnology
NASDAQ
BCLI Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
BCLI Latest news
PRNewsWire
Neutral
BrainStorm to Announce Third Quarter Financial Results and Provide a Corporate Update
2021-10-25 07:00

NEW YORK, Oct. 25, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the third quarter ended September 30, 2021, and provide a corporate update, at 8:00 a.m. Eastern Time on November 15, 2021.

PRNewsWire
Neutral
BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at NYSCF 2021 VIRTUAL Meeting
2021-10-18 07:30

NEW YORK, Oct. 18, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Therapeutic Benefits of MSC-NTF (NurOwn®) Exosomes in Acute Lung Injury Models" at the NYSCF 2021 VIRTUAL Meeting, being held on October 19-20, 2021.  The poster will be presented tomorrow, October 19, at 3:45 – 5:00pm Eastern Time.

PRNewsWire
Neutral
Phase 2 Clinical Trial Data of NurOwn® in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
2021-10-14 07:00

NEW YORK, Oct. 14, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, will present findings from a multicenter, open label clinical trial of NurOwn® in progressive multiple sclerosis.  The study, "Phase 2 Safety and Efficacy Study of Intrathecal MSC-NTF cells in Progressive Multiple Sclerosis," will be delivered in an oral presentation today at the fully digital 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

PRNewsWire
Neutral
BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting October 6th, 2021
2021-10-06 17:00

NEW YORK, Oct. 6, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "CSF biomarker correlations with primary outcome in NurOwn Phase 3 clinical trial" will be presented as a scientific poster at the fully digital 2021 Northeast Amyotrophic Lateral Sclerosis Consortium® (NEALS) conference.  The presentation will be delivered by James Berry, M.D.

PRNewsWire
Neutral
BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa
2021-10-04 06:00

NEW YORK, Oct. 4, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that Stacy Lindborg, Ph.D., Executive Vice President and Head of Global Clinical Research, will deliver a presentation at the 2021 Cell & Gene Meeting on the Mesa, being held as a hybrid conference October 12-14, and October 19-20, 2021.

PRNewsWire
Neutral
BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS
2021-10-01 07:28

NEW YORK, Oct. 1, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "Phase 2 Safety and Efficacy Study of Intrathecal MSC-NTF cells in Progressive Multiple Sclerosis" will be presented in an oral presentation at the fully digital 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).  The presentation will be delivered by Jeffrey Cohen, M.D.

Seeking Alpha
Neutral
BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q2 2021 Results - Earnings Call Transcript
2021-08-05 12:29

BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q2 2021 Results - Earnings Call Transcript

PRNewsWire
Neutral
BrainStorm Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
2021-08-05 07:00

NEW YORK, Aug. 5, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended June 30, 2021 and provided a corporate update. "We continue to take important steps to advance NurOwn in ALS and progressive MS and position ourselves for sustained success," said Chaim Lebovits, Chief Executive Officer of BrainStorm.

PRNewsWire
Neutral
BrainStorm Increases Commercial Manufacturing Capacity; Granted GMP Certification for a Second Production Site in Israel
2021-07-27 06:00

NEW YORK, July 27, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that is has received Good Manufacturing Practice (GMP) approval from the Israel Ministry of Health for three state-of-the-art cleanrooms leased by the Company at the Tel Aviv Sourasky Medical Center ("Sourasky Hospital") in Tel Aviv, Israel. The GMP approval confirms that these cleanrooms are compliant with Israeli GMPs, which are aligned with European Union (EU) GMPs, and more than doubles the Company's capacity to manufacture and ship NurOwn® into the EU and local Israeli markets.

PRNewsWire
Neutral
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
2021-07-26 06:00

NEW YORK, July 26, 2021 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2021, and provide a corporate update, at 8:00 a.m. Eastern Time on August 05, 2021.

Loading more news...